Endocrinol Metab.  2010 Sep;25(3):213-216. 10.3803/EnM.2010.25.3.213.

Sustained Maintenance of Normal Insulin-like Growth Factor-I during Pregnancy and Successful Delivery in an Acromegalic Patient with Octreotide-LAR(R) Treatment

• Kim SK
• Jung JH
• Kim JH
• Hur KY
• Tan AH
• Kim HK
• Lee JI
• Chung HS
• Kim KW

• KMID: 2169059
• DOI: http://doi.org/10.3803/EnM.2010.25.3.213

Abstract

We report here on a 34-year-old Korean woman with active acromegaly and who received Octreotide-LAR(R) for 12 months following transsphenoidal pituitary surgery. During Octreotide-LAR(R) treatment, the clinical improvement was paralleled with the decrease of the growth hormone levels to 1.1 ng/mL and the insulin-like growth factor-I (IGF-I) levels to 345.5 ng/mL. Octreotide-LAR(R) was discontinued when the patient was found to be at the 12th week of pregnancy. During pregnancy, the patient experienced clinical well-being and she maintained her IGF-I levels within the normal range for her age-matched despite discontinuation of Octreotide-LAR(R) treatment at early gestation. She delivered a full-term healthy male infant. The serum IGF-I levels of the patient increased progressively increased after delivery. This report describes a successful pregnancy in an acromegalic woman who was exposed to Octreotide-LAR(R) during the early gestational period. She and who showed an unexpected pattern of persistently normal IGF-I levels through the pregnancy despite discontinuation of Octreotide-LAR(R) therapy.

Keyword

Acromegaly; Insulin-like growth factor-I; Octreotide; Pregnancy

MeSH Terms

Acromegaly
Adult
Female
Growth Hormone
Humans
Infant
Insulin-Like Growth Factor I
Male
Octreotide
Pregnancy
Reference Values
Growth Hormone
Insulin-Like Growth Factor I
Octreotide

Figure

• 

  Fig. 1. Comparisons of sellar MRI performed at preoperative (A), postoperative (B) and post-delivery period (C).

• 

  Fig. 2. Change of serum growth hormone (GH) concentration in 75 g oral glucose loading test at initial diagnosis.

• 

  Fig. 3. Clinical course of serum levels of IGF-I and growth hormone (GH) during pregnancy and postpartum period.

Reference

References

1. Takano T, Saito J, Soyama A, Ito H, Iizuka T, Yoshida T, Nishikawa T. Normal delivery following an uneventful pregnancy in a Japanese acromegalic patient after discontinuation of octreotide long acting release formulation at an early phase of pregnancy. Endocr J. 53:209–212. 2006.

2. Fassnacht M, Capeller B, Arlt W, Steck T, Allolio B. Octreotide LAR treatment throughout pregnancy in an acromegalic woman. Clin Endocrinol (Oxf). 55:411–415. 2001.

3. Takeuchi K, Funakoshi T, Oomori S, Maruo T. Successful pregnancy in an acromegalic woman treated with octreotide. Obstet Gynecol. 93:848. 1999.

4. Serri O, Lanoie G. Successful pregnancy in a woman with acromegaly treated with Octreotide Long-acting Release. Endocrinologist. 13:17–19. 2003.

5. Hierl T, Ziegler R, Kasperk C. Pregnancy in persistent acromegaly. Clin Endocrinol (Oxf). 53:262–263. 2000.

6. Goluboff LG, Ezrin C. Effect of pregnancy on the somatotroph and the prolactin cell of the human adenohypophysis. J Clin Endocrinol Metab. 29:1533–1538. 1969.

7. Molitch ME. Pregnancy and the hyperprolactinemic woman. N Engl J Med. 312:1364–1370. 1985.

8. Demura R, Ono M, Demura H, Shizume K, Oouchi H. Prolactin directly inhibits basal as well as gonadotropin-stimulated secretion of progesterone and 17 beta-estradiol in the human ovary. J Clin Endocrinol Metab. 54:1246–1250. 1982.

9. Choi H, Lee Y, Chung IH, Koh JH, Kim MJ, Shin YG, Chung CH. A case of two consecutive deliveries in a woman with acromegaly. Korean J Med. 67:662–666. 2004.

10. Wilson DM, Bennett A, Adamson GD, Nagashima RJ, Liu F, DeNatale ML, Hintz RL, Rosenfeld RG. Somatomedins in pregnancy: a cross-sectional study of insulinlike growth factors I and II and somatomedin peptide content in normal human pregnancies. J Clin Endocrinol Metab. 55:858–861. 1982.

11. Beckers A, Stevenaert A, Foidart JM, Hennen G, Frankenne F. Placental and pituitary growth hormone secretion during pregnancy in acromegalic women. J Clin Endocrinol Metab. 71:725–731. 1990.

12. Herman-Bonert V, Seliverstov M, Melmed S. Pregnancy in acromegaly: successful therapeutic outcome. J Clin Endocrinol Metab. 83:727–731. 1998.

13. Okada Y, Morimoto I, Ejima K, Yoshida K, Kashimura M, Fujihira T, Eto S. A case of active acromegalic woman with a marked increase in serum insulinlike growth factor-I levels after delivery. Endocr J. 44:117–120. 1997.

14. Clemmons DR, Underwood LE, Ridgway EC, Kliman B, Kjellberg RN, Van Wyk JJ. Estradiol treatment of acromegaly. Reduction of immunoreactive somatomedin-C and improvement in metabolic status. Am J Med. 69:571–575. 1980.

15. Parkinson C, Ryder WD, Trainer PJ. Sensus Acromegaly Study Group. The relationship between serum GH and serum IGF-I in acromegaly is gender-specific. J Clin Endocrinol Metab. 86:5240–5244. 2001.

16. Lee KW, Nam MS. Medical therapy of somato statin analog in acromegaly. J Korean Soc Endocrinol. 17:629–634. 2002.

17. Mikhail N. Octreotide treatment of acromegaly during pregnancy. Mayo Clin Proc. 77:297–298. 2002.

18. de Menis E, Billeci D, Marton E, Gussoni G. Uneventful pregnancy in an acromegalic patient treated with slow-release lanreotide: a case report. J Clin Endocrinol Metab. 84:1489. 1999.

19. Caron P, Gerbeau C, Pradayrol L. Maternal-fetal transfer of octreotide. N Engl J Med. 333:601–602. 1995.

20. Caron P, Gerbeau C, Pradayrol L, Simonetta C, Bayard F. Successful pregnancy in an infertile woman with a thyrotropin-secreting macroadenoma treated with somatostatin analog (octreotide). J Clin Endocrinol Metab. 81:1164–1168. 1996.